Drug company is targeted for refusing to adopt ban on distribution of execution drugBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g6452 (Published 24 October 2014) Cite this as: BMJ 2014;349:g6452
- Owen Dyer
A US drug company has been targeted by investors after declining to participate fully in the embargo against providing lethal injection drugs to states with the death penalty.
The company, Mylan, of Pennsylvania, makes rocuronium bromide, which Alabama has just adopted in its new execution drug protocol. Although the company does not sell directly to corrections departments in death penalty states, it has not extracted commitments from resellers to refrain from such sales.
Since 2011 the European Union has banned the export of sodium thiopental, a key anesthetic in lethal injections, and some small drug manufacturers outside the EU have also refused to sell sodium thiopental and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial